Fibrocell's gene therapy gets rare pediatric disease designation for localized scleroderma

FDA granted rare pediatric disease designation to FCX-013 (GM-HDF-COL7) from Fibrocell Science Inc. (NASDAQ:FCSC) to treat moderate to severe localized scleroderma. In 4Q17, Fibrocell plans to submit an IND to FDA for FCX-013, which also has Orphan Drug designation in the U.S. for localized scleroderma...